FdaApplication
BLA 125774
Identifiers
- fda_app_no: BLA125774
Properties
| Property | Value |
|---|---|
| applicant_name | Krystal Biotech, Inc. |
| application_type | BLA |
| approval_date | 2023-05-19 |
Revenue by product
VYJUVEK
| Period | Revenue |
|---|---|
| Q2 2026 | $119.2M† |
| Q1 2026 | $116.4M† |
| Q4 2025 | $107.1M† |
| Q3 2025 | $97.8M† |
| Q2 2025 | $96.0M† |
| Q1 2025 | $88.2M† |
| Q4 2024 | $91.1M† |
| Q3 2024 | $83.8M† |
| Q2 2024 | $70.3M† |
| Q1 2024 | $45.3M† |
| Q4 2023 | $42.1M† |
| Q3 2023 | $8.6M† |
| Q2 2023 | $0.0M† |
| Q1 2023 | $0.0M† |
| Q4 2022 | $0.0M† |
| Q3 2022 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VYJUVEK | — | 5.0x10^9 PFU/mL | Gel |
1 product